Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0533. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 19/20 | 1.00 |
| ▸ | PPARA | Q07869 | 12/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | CYP4X1 | Q8N118 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | TACR2 | P21452 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0533 SCHEMBL671319 | 1.00 | PPARG (1.00) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| Mk-0533 SCHEMBL530539 | 1.00 | PPARG (1.00) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| Mk-0533 SCHEMBL13384215 | 1.00 | PPARG (1.00) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL671320 | 0.94 | PPARG (0.89) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL530540 | 0.94 | PPARG (0.89) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2599627 | 0.94 | PPARG (0.89) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL14447483 | 0.93 | PPARG (0.87) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL14447496 | 0.93 | PPARG (0.87) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2901375 | 0.92 | PPARG (0.86) | PPARGPPARACYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2898987 | 0.92 | PPARG (0.86) | PPARGPPARACYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4291239-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2023-12-20 | — | — | EP | disclosed |
| US-20230064246-A1 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4055192-A1 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | PPARG 2063/4885PPARA 1810/4885CYP2C9 4879/4885 |
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | PPARG 141/4885PPARA 203/4885CYP2C9 4313/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | PPARG 141/4885PPARA 203/4885CYP2C9 4313/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | PPARG 158/4885PPARA 215/4885CYP2C9 4587/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | PPARG 1796/4885PPARA 3003/4885CYP2C9 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.